J&J enters dermal filler market
This article was originally published in The Gray Sheet
Executive Summary
OrthoNeutrogena, a division of Ortho-McNeil-Janssen Pharmaceuticals which is part of Johnson & Johnson, enters the U.S. aesthetic facial dermal filler market with the June 27 PMA approval of its Evolence porcine collagen-based filler for correction of moderate to deep facial wrinkles and folds. The market roll-out will be conducted "throughout the second half of 2008" in coordination with physician training, the company says. Evolence has been available outside the U.S. since 2004. The product, which "does not require a pre-test" on prospective recipients, is "clinically proven to last through six months," J&J says. The firm plans to file additional data for 12-month duration approval. Competitors include Medicis (Restylane and Perlane), Allergan (Juvederm), BioForm (Radiesse), Artes Medical (ArteFill), Mentor (Prevelle Silk), and Anika (Elevess).Medicis (Restylane